Keywords: bristol-myers, squibb, earnings, sink, generic, competition, takes
Bristol-Myers Squibb's earnings sink as generic competition takes hold
Article | 06 May 2002
Net income at Bristol-Myers Squibb (excluding several non-recurringitems) has fallen 30% to $875 million for the first quarter of 2002, or $0.45 per share. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
